{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:20:39Z","timestamp":1771305639975,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Giant Pledge through the Royal Marsden Cancer Charity"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>There is an urgent need for early radiological markers predicting survival in paediatric rhabdomyosarcoma patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To analyse the predictive value of early radiological tumour volume response to chemotherapy in non-metastatic rhabdomyosarcoma patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The European paediatric Soft tissue sarcoma Study Group (E<jats:italic>p<\/jats:italic>SSG) RMS 2005 study prospectively included non-metastatic rhabdomyosarcoma patients. Patients with Intergroup Rhabdomyosarcoma Studies (IRS) postsurgical Group III (i.e. measurable disease) at diagnosis, with three tumour diameters available at diagnosis and following three cycles of chemotherapy, were included. Tumour response was categorized as complete response, partial response, minor partial response, stable disease, or progressive disease. Patients with progressive disease were excluded from analyses. Failure-free survival and overall survival were estimated with Kaplan-Meier using a landmark analysis. Prognostic factors were assessed using Cox proportional hazards analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 1,674 patients aged\u2009&lt;\u200918\u00a0years at diagnosis included in the E<jats:italic>p<\/jats:italic>SSG RMS 2005 study, 613 patients (median age 4.2\u00a0years, interquartile range 2.2\u20138.0, 346 males) were eligible for analysis. After three cycles of chemotherapy, 48 patients reached complete response, 371 partial response, 139 minor partial response, 48 stable disease, and seven patients progressive disease. Univariate Cox proportional hazards model showed no significant difference between response groups for failure-free survival or overall survival. In multivariate Cox regression analysis, tumour volume response was not an independent prognostic factor for failure-free survival or overall survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Early radiological tumour volume response after the third cycle of neoadjuvant chemotherapy, with exclusion of progressive disease, does not predict survival in paediatric rhabdomyosarcoma patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00247-025-06359-3","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T08:14:12Z","timestamp":1755159252000},"page":"2160-2170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early radiologic tumour volume response in non-metastatic rhabdomyosarcoma is not predictive for survival"],"prefix":"10.1007","volume":"55","author":[{"given":"Isabelle S.A.","family":"de Vries","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Morosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Bisogno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Minard-Colin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Coppadoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Zanetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Orbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Moalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Ben-Arush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Devalck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roelof","family":"van Ewijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieran","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meriel","family":"Jenney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Chisholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Guillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Mandeville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes H. M.","family":"Merks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick R.","family":"Van Rijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"6359_CR1","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2011.40.3287","volume":"30","author":"O Oberlin","year":"2012","unstructured":"Oberlin O, Rey A, Sanchez De Toledo J et al (2012) Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatr. J Clin Oncol 30:2457\u20132465","journal-title":"J Clin Oncol"},{"key":"6359_CR2","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1200\/JCO.2005.08.130","volume":"23","author":"MCG Stevens","year":"2005","unstructured":"Stevens MCG, Rey A, Bouvet N et al (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology-SIOP malignant mesenchymal tumor 89. J Clin Oncol 23:2618\u20132628","journal-title":"J Clin Oncol"},{"key":"6359_CR3","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/S0959-8049(98)00024-0","volume":"34","author":"F Flamant","year":"1998","unstructured":"Flamant F, Rodary C, Rey A et al (1998) Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer 34:1050\u20131062","journal-title":"Eur J Cancer"},{"key":"6359_CR4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/pbc.23292","volume":"58","author":"G Bisogno","year":"2012","unstructured":"Bisogno G, Pastore G, Perilongo G et al (2012) Long-term results in childhood rhabdomyosarcoma: a report from the Italian cooperative study RMS 79. Pediatr Blood Cancer 58:872\u2013876","journal-title":"Pediatr Blood Cancer"},{"key":"6359_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207\u2013214","journal-title":"Cancer"},{"key":"6359_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(18)30337-1","volume":"19","author":"G Bisogno","year":"2018","unstructured":"Bisogno G, Jenney M, Bergeron C et al (2018) Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol 19:1061\u20131071","journal-title":"Lancet Oncol"},{"key":"6359_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"6359_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-011-2008-4","author":"SD Voss","year":"2011","unstructured":"Voss SD (2011) Pediatric oncology and the future of oncological imaging. Pediatr Radiol. https:\/\/doi.org\/10.1007\/s00247-011-2008-4","journal-title":"Pediatr Radiol"},{"key":"6359_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00247-003-1067-6","volume":"33","author":"K McHugh","year":"2003","unstructured":"McHugh K, Kao S (2003) Can paediatric radiologists resist RECIST (response evaluation criteria in solid tumours)? Pediatr Radiol 33:739\u2013743","journal-title":"Pediatr Radiol"},{"key":"6359_CR10","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/cncr.31157","volume":"124","author":"B Vaarwerk","year":"2018","unstructured":"Vaarwerk B, van der Lee JH, Breunis WB et al (2018) Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: a report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study. Cancer 124:1016\u20131024","journal-title":"Cancer"},{"key":"6359_CR11","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1200\/JCO.2006.10.4257","volume":"25","author":"M Burke","year":"2007","unstructured":"Burke M, Anderson JR, Kao SC et al (2007) Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the intergroup rhabdomyosarcoma study-IV experience - a report from the soft tissue sarcoma committee of the Children\u2019s Oncology Group. J Clin Oncol 25:4909\u20134913","journal-title":"J Clin Oncol"},{"key":"6359_CR12","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.ejca.2013.11.031","volume":"50","author":"AR Rosenberg","year":"2014","unstructured":"Rosenberg AR, Anderson JR, Lyden E et al (2014) Early response as assessed by anatomic imaging does not predict failure-free survival among patients with group III rhabdomyosarcoma: a report from the Children\u2019s Oncology Group. Eur J Cancer 50:816\u2013823","journal-title":"Eur J Cancer"},{"key":"6359_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12123808","volume":"12","author":"G Orsatti","year":"2020","unstructured":"Orsatti G, Morosi C, Giraudo C et al (2020) Pediatric rhabdomyosarcomas: three-dimensional radiological assessments after induction chemotherapy predict survival better than one-dimensional and two-dimensional measurements. Cancers (Basel) 12:1\u201316","journal-title":"Cancers (Basel)"},{"key":"6359_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/pbc.25207","volume":"62","author":"TM Dantonello","year":"2015","unstructured":"Dantonello TM, Stark M, Timmermann B et al (2015) Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma. Pediatr Blood Cancer 62:16\u201323","journal-title":"Pediatr Blood Cancer"},{"key":"6359_CR15","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1200\/JCO.2009.25.0803","volume":"28","author":"A Ferrari","year":"2010","unstructured":"Ferrari A, Miceli R, Meazza C et al (2010) Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J Clin Oncol 28:1322\u20131328","journal-title":"J Clin Oncol"},{"key":"6359_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30617-5","author":"G Bisogno","year":"2019","unstructured":"Bisogno G, De Salvo GL, Bergeron C et al (2019) Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(19)30617-5","journal-title":"Lancet Oncol"},{"key":"6359_CR17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.18.01535","volume":"37","author":"B Vaarwerk","year":"2019","unstructured":"Vaarwerk B, Bisogno G, McHugh K et al (2019) Indeterminate pulmonary nodules at diagnosis in rhabdomyosarcoma: are they clinically significant? A report from the European paediatric soft tissue sarcoma study group. J Clin Oncol 37:723\u2013730","journal-title":"J Clin Oncol"},{"key":"6359_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.27725","volume":"66","author":"F Gu\u00e9rin","year":"2019","unstructured":"Gu\u00e9rin F, Rogers T, Minard-Colin V et al (2019) Outcome of localized liver-bile duct rhabdomyosarcoma according to local therapy: a report from the European Paediatric Soft-Tissue Sarcoma Study Group (EpSSG)-RMS 2005 study. Pediatr Blood Cancer 66:1\u20138","journal-title":"Pediatr Blood Cancer"},{"key":"6359_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejca.2021.04.007","volume":"151","author":"H Glosli","year":"2021","unstructured":"Glosli H, Bisogno G, Kelsey A et al (2021) Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: experience of the European paediatric soft tissue sarcoma Study Group (EpSSG) \u2013 RMS2005 study. Eur J Cancer 151:84\u201393","journal-title":"Eur J Cancer"},{"key":"6359_CR20","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1200\/JCO.22.02093","volume":"41","author":"G Bisogno","year":"2023","unstructured":"Bisogno G, Minard-Colin V, Zanetti I et al (2023) Nonmetastatic rhabdomyosarcoma in children and adolescents: overall results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 study. J Clin Oncol 41:2342\u20132349","journal-title":"J Clin Oncol"},{"key":"6359_CR21","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.ejso.2022.03.001","volume":"48","author":"CEJ Terwisscha van Scheltinga","year":"2022","unstructured":"Terwisscha van Scheltinga CEJ, Wijnen MHWA, Martelli H et al (2022) In transit metastases in children, adolescents and young adults with localized rhabdomyosarcoma of the distal extremities: analysis of the EpSSG RMS 2005 study. Eur J Surg Oncol 48:1536\u20131542","journal-title":"Eur J Surg Oncol"},{"key":"6359_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejca.2021.10.031","volume":"160","author":"O Slater","year":"2022","unstructured":"Slater O, Gains JE, Kelsey AM et al (2022) Localised rhabdomyosarcoma in infants (<12 months) and young children (12\u201336 months of age) treated on the EpSSG RMS 2005 study. Eur J Cancer 160:206\u2013214","journal-title":"Eur J Cancer"},{"key":"6359_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2352-4642(22)00121-3","volume":"6","author":"A Ferrari","year":"2022","unstructured":"Ferrari A, Chisholm JC, Jenney M et al (2022) Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric soft tissue sarcoma study group (EpSSG) protocols: a cohort study. Lancet Child Adolesc Health 6:545\u2013554","journal-title":"Lancet Child Adolesc Health"},{"key":"6359_CR24","doi-asserted-by":"publisher","unstructured":"Bisogno G, Minard-Colin V, Arush M Ben, et al (2022) Congenital rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group. Pediatr Blood Cancer 69. https:\/\/doi.org\/10.1002\/pbc.29376","DOI":"10.1002\/pbc.29376"},{"key":"6359_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejca.2022.05.033","volume":"172","author":"M Ben-Arush","year":"2022","unstructured":"Ben-Arush M, Minard-Colin V, Scarzello G et al (2022) Therapy and prognostic significance of regional lymph node involvement in embryonal rhabdomyosarcoma: a report from the European paediatric soft tissue sarcoma study group. Eur J Cancer 172:119\u2013129","journal-title":"Eur J Cancer"},{"key":"6359_CR26","doi-asserted-by":"publisher","first-page":"7580","DOI":"10.1002\/cam4.3365","volume":"9","author":"SEJ Terwisscha van Scheltinga","year":"2020","unstructured":"Terwisscha van Scheltinga SEJ, Wijnen MHWA, Martelli H et al (2020) Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG-RMS2005 study. Cancer Med 9:7580\u20137589","journal-title":"Cancer Med"},{"key":"6359_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.28479","volume":"67","author":"TN Rogers","year":"2020","unstructured":"Rogers TN, De Corti F, Burrieza GG et al (2020) Paratesticular rhabdomyosarcoma\u2014impact of locoregional approach on patient outcome: a report from the European paediatric Soft tissue sarcoma Study Group (EpSSG). Pediatr Blood Cancer 67:1\u201310","journal-title":"Pediatr Blood Cancer"},{"key":"6359_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","volume":"26","author":"CJ Morgan","year":"2019","unstructured":"Morgan CJ (2019) Landmark analysis: a primer. J Nucl Cardiol 26:391\u2013393","journal-title":"J Nucl Cardiol"},{"key":"6359_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","volume":"69","author":"D Schoenfeld","year":"1982","unstructured":"Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69:239\u2013241","journal-title":"Biometrika"},{"key":"6359_CR30","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1200\/JCO.2010.29.0247","volume":"28","author":"AY Minn","year":"2010","unstructured":"Minn AY, Lyden ER, Anderson JR et al (2010) Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803 - a report from the children\u2019s oncology group. J Clin Oncol 28:4228\u20134232","journal-title":"J Clin Oncol"},{"key":"6359_CR31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030510","volume":"13","author":"R van Ewijk","year":"2021","unstructured":"van Ewijk R, Vaarwerk B, Breunis WB et al (2021) The value of early tumor size response to chemotherapy in pediatric rhabdomyosarcoma. Cancers (Basel) 13:1\u201315","journal-title":"Cancers (Basel)"},{"key":"6359_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3109\/02841861003705794","volume":"49","author":"C Suzuki","year":"2010","unstructured":"Suzuki C, Torkzad MR, Jacobsson H et al (2010) Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol (Madr) 49:509\u2013514","journal-title":"Acta Oncol (Madr)"},{"key":"6359_CR33","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1148\/radiol.13122607","volume":"269","author":"RA Schoot","year":"2013","unstructured":"Schoot RA, McHugh K, Van Rijn RR et al (2013) Response assessment in pediatric rhabdomyosarcoma: can response evaluation criteria in solid tumors replace three-dimensional volume assessments? Radiology 269:870\u2013878","journal-title":"Radiology"},{"key":"6359_CR34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22","author":"RA Schoot","year":"2023","unstructured":"Schoot RA, Shulkin BL, Van Rijn RR, Von Kalle T (2023) Pediatric rhabdomyosarcoma protocols should include more detailed imaging guidelines to ensure homogeneous response assessment. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.22","journal-title":"J Clin Oncol"},{"key":"6359_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ejca.2022.05.037","volume":"172","author":"SM Kelly","year":"2022","unstructured":"Kelly SM, Effeney R, Gaze MN et al (2022) QUARTET: a SIOP Europe project for quality and excellence in radiotherapy and imaging for children and adolescents with cancer. Eur J Cancer 172:209\u2013220","journal-title":"Eur J Cancer"},{"key":"6359_CR36","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s00247-014-3120-z","volume":"45","author":"G Norman","year":"2015","unstructured":"Norman G, Fayter D, Lewis-Light K et al (2015) Mind the gap: extent of use of diffusion-weighted MRI in children with rhabdomyosarcoma. Pediatr Radiol 45:778\u2013781","journal-title":"Pediatr Radiol"},{"key":"6359_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2014-006030","volume":"5","author":"G Norman","year":"2015","unstructured":"Norman G, Fayter D, Lewis-Light K et al (2015) An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review. BMJ Open 5:1\u20138","journal-title":"BMJ Open"},{"key":"6359_CR38","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1007\/s00247-023-05745-z","volume":"53","author":"R van Ewijk","year":"2023","unstructured":"van Ewijk R, Chatziantoniou C, Adams M et al (2023) Quantitative diffusion-weighted MRI response assessment in rhabdomyosarcoma: an international retrospective study on behalf of the European paediatric soft tissue sarcoma study group imaging committee. Pediatr Radiol 53:2539\u20132551","journal-title":"Pediatr Radiol"},{"key":"6359_CR39","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/tomography8020058","volume":"8","author":"SC Partridge","year":"2022","unstructured":"Partridge SC, Steingrimsson J, Newitt DC et al (2022) Impact of alternate b-value combinations and metrics on the predictive performance and repeatability of diffusion-weighted MRI in breast cancer treatment: results from the ECOG-ACRIN A6698 trial. Tomography 8:701\u2013717","journal-title":"Tomography"},{"key":"6359_CR40","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1007\/s00259-021-05610-x","volume":"49","author":"JL Vos","year":"2022","unstructured":"Vos JL, Zuur CL, Smit LA et al (2022) [18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 49:2010\u20132022","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Pediatric Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00247-025-06359-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00247-025-06359-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00247-025-06359-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:36:56Z","timestamp":1760096216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00247-025-06359-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["6359"],"URL":"https:\/\/doi.org\/10.1007\/s00247-025-06359-3","relation":{},"ISSN":["1432-1998"],"issn-type":[{"value":"1432-1998","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alice\u2019s Arc, a children\u2019s cancer charity focusing on rhabdomyosarcoma, UK (alicesarc.org), has funded data management and statistical processing for current analyses. Julia Chisholm is supported by the Giant Pledge through the Royal Marsden Cancer Charity and this independent research is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The other authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}